Abstract
The overexpression of Tumor Necrosis Factor (TNF) is directly related to the development of several autoimmune diseases, such as rheumatoid and psoriatic arthritis, inflammatory bowel disease, Crohn's disease, refractory asthma, and multiple sclerosis. Receptor Activator of Nuclear Factor Kappa- B Ligand (RANKL) belongs to the TNF family and is the primary mediator of osteoclast-induced bone resorption through interaction with its receptor RANK. The function of RANKL is physiologically inhibited by the action of osteoprotegerin (OPG), which is a decoy receptor that binds to RANKL and prevents the process of osteoclastogenesis. Malfunction among RANK/RANKL/OPG can also result in bone loss diseases, including postmenopausal osteoporosis, rheumatoid arthritis, bone metastasis and multiple myeloma. To disrupt the unwanted functions of TNF and RANKL, current attempts focus on blocking TNF and RANKL binding to their receptors. In this review, we present the research efforts toward the development of low-molecular-weight pharmaceuticals that directly block the detrimental actions of TNF and RANKL.
Keywords: Tumor Necrosis Factor (TNF), osteoprotegerin (OPG), postmenopausal osteoporosis, rheumatoid arthritis, disease, metastasis.
Current Topics in Medicinal Chemistry
Title:Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Volume: 18 Issue: 8
Author(s): Georgia Melagraki, Georgios Leonis, Evangelos Ntougkos, Vagelis Rinotas, Christos Papaneophytou, Thomas Mavromoustakos, George Kontopidis, Eleni Douni, George Kollias*Antreas Afantitis*
Affiliation:
- Division of Immunology, Biomedical Sciences Research Center `Alexander Fleming`, Vari,Greece
- Division of Immunology, Biomedical Sciences Research Center `Alexander Fleming`, Vari,Greece
Keywords: Tumor Necrosis Factor (TNF), osteoprotegerin (OPG), postmenopausal osteoporosis, rheumatoid arthritis, disease, metastasis.
Abstract: The overexpression of Tumor Necrosis Factor (TNF) is directly related to the development of several autoimmune diseases, such as rheumatoid and psoriatic arthritis, inflammatory bowel disease, Crohn's disease, refractory asthma, and multiple sclerosis. Receptor Activator of Nuclear Factor Kappa- B Ligand (RANKL) belongs to the TNF family and is the primary mediator of osteoclast-induced bone resorption through interaction with its receptor RANK. The function of RANKL is physiologically inhibited by the action of osteoprotegerin (OPG), which is a decoy receptor that binds to RANKL and prevents the process of osteoclastogenesis. Malfunction among RANK/RANKL/OPG can also result in bone loss diseases, including postmenopausal osteoporosis, rheumatoid arthritis, bone metastasis and multiple myeloma. To disrupt the unwanted functions of TNF and RANKL, current attempts focus on blocking TNF and RANKL binding to their receptors. In this review, we present the research efforts toward the development of low-molecular-weight pharmaceuticals that directly block the detrimental actions of TNF and RANKL.
Export Options
About this article
Cite this article as:
Melagraki Georgia , Leonis Georgios , Ntougkos Evangelos , Rinotas Vagelis , Papaneophytou Christos , Mavromoustakos Thomas , Kontopidis George , Douni Eleni , Kollias George *, Afantitis Antreas*, Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL), Current Topics in Medicinal Chemistry 2018; 18 (8) . https://dx.doi.org/10.2174/1568026618666180607084430
DOI https://dx.doi.org/10.2174/1568026618666180607084430 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept
Current Rheumatology Reviews Yellow Lupine Cyclophilin Interacts with Nucleic Acids
Protein & Peptide Letters Epidemiology of Psoriasis
Current Drug Targets - Inflammation & Allergy Monocyte Cyclooxygenase-2 Activity: A New Therapeutic Target for Atherosclerosis?
Current Drug Targets - Cardiovascular & Hematological Disorders Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses
Current Drug Targets Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews Management of Painful Symptoms with Duloxetine: A Review of the Efficacy in Pre-Clinical and Clinical Studies
Current Drug Therapy Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment
Current Drug Targets Discovery of 4-Aryl-4H-Chromenes as Potent Apoptosis Inducers Using a Cell- and Caspase-Based Anti-Cancer Screening Apoptosis Program (ASAP): SAR Studies and the Identification of Novel Vascular Disrupting Agents
Anti-Cancer Agents in Medicinal Chemistry JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry History of Autoimmune Pancreatitis and Mikuliczs Disease
Current Immunology Reviews (Discontinued) 1, 2, 4-Oxadiazole Incorporated Ketoprofen Analogues in Search of Safer Non-steroidal Anti-inflammatory Agents: Design, Syntheses, Biological Evaluation and Molecular Docking Studies
Letters in Drug Design & Discovery Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Current Medicinal Chemistry Platelet-neutrophil Interactions as a Target for Prevention and Treatment of Transfusion- related Acute Lung Injury
Current Pharmaceutical Design Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Anti-IL-12/23 in Crohn's Disease: Bench and Bedside
Current Drug Targets